These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 234293)

  • 1. Management of recurrent melanoma of the extremity.
    Shingleton WW; Seigler HF; Stocks LH; Downs RW
    Cancer; 1975 Mar; 35(3):574-9. PubMed ID: 234293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mumps virus and BCG vaccine in metastatic melanoma.
    Minton JP
    Arch Surg; 1973 Apr; 106(4):503-6. PubMed ID: 4572347
    [No Abstract]   [Full Text] [Related]  

  • 3. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities--long-term follow-up of a randomised trial.
    Olofsson Bagge R; Mattsson J; Hafström L
    Int J Hyperthermia; 2014 Aug; 30(5):295-8. PubMed ID: 25144818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guérin and hyperthermic perfusion.
    Storm FK; Sparks FC; Morton DL
    Surg Gynecol Obstet; 1979 Jul; 149(1):17-21. PubMed ID: 451822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of administering B.C.G. to patients with melanoma.
    Grant RM; Mackie R; Cochran AJ; Murray EL; Hoyle D; Ross C
    Lancet; 1974 Nov; 2(7889):1096-100. PubMed ID: 4139404
    [No Abstract]   [Full Text] [Related]  

  • 6. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.
    Seigler HF; Shingleton WW; Pickrell KL
    Plast Reconstr Surg; 1975 Mar; 55(3):294-8. PubMed ID: 1118487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
    Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
    Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
    Kokoschka EM; Cerni C; Micksche M
    Oncology; 1977; 34(5):229-33. PubMed ID: 917456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intralesional immunotherapy of melanoma with BCG.
    Rosenberg SA; Rapp HJ
    Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCG immunotherapy of malignant melanoma: summary of a seven-year experience.
    Morton DL; Eilber FR; Holmes EC; Hunt JS; Ketcham AS; Silverstein MJ; Sparks FC
    Ann Surg; 1974 Oct; 180(4):635-43. PubMed ID: 4412271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
    Coates AS; Peters M
    Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V; Knopf B
    Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH; Deutschmann EM; Schultheis W; Deicher H
    Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of melanoma with intralesional BCG.
    Bornstein RS; Mastrangelo MJ; Sulit H; Chee D; Yarbro JW; Prehn LM; Prehn RT
    Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
    [No Abstract]   [Full Text] [Related]  

  • 15. [Intratumor BCG immunotherapy of advanced malignant melanoma].
    Jassem J
    Nowotwory; 1981; 31(1):67-70. PubMed ID: 7290998
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunotherapy of malignancy in humans. Current status.
    Holmes EC; Eilber FR; Morton DL
    JAMA; 1975 Jun; 232(10):1052-5. PubMed ID: 236402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multiphase immunotherapy regimen for human melanoma: clinical and laboratory results.
    Levy NL; Seigler HF; Shingleton WW
    Cancer; 1974 Oct; 34(4 Suppl):suppl:1548-57. PubMed ID: 4421918
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapy of melanoma with BCG: two fatalities following intralesional injection.
    McKhann CF; Hendrickson CG; Spitler LE; Gunnarsson A; Banerjee D; Nelson WR
    Cancer; 1975 Feb; 35(2):514-20. PubMed ID: 234291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
    Lieberman R; Wybran J; Epstein W
    Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-inventing intratumoral immunotherapy for melanoma.
    Triozzi PL; Tuthill RJ; Borden E
    Immunotherapy; 2011 May; 3(5):653-71. PubMed ID: 21554094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.